John S. Tokarski

5.7k citations

43 papers · 2.0k indexed · 1 hit paper · h-index 23

Hematology top 2%
Genetics top 5%
Computational Theory and Mathematics top 1%
- Computational Drug Discovery Methods 7
Organic Chemistry top 5%
Oncology top 10%
- HER2/EGFR in Cancer Research 6
- Cancer-related Molecular Pathways 5
- Cytokine Signaling Pathways and Interactions 5
Cell Biology
- Microtubule and mitosis dynamics 6
Molecular Biology
- Melanoma and MAPK Pathways 4
- Cancer therapeutics and mechanisms 4
- Angiogenesis and VEGF in Cancer 4

Co-authors: A. J. Hopfinger Louis J. Lombardo Dianlin Xie Shen Wang Chaya Duraiswami Magaly Girão Albuquerque Susan E. Kiefer John A. Newitt
Cited by: Hematology Genetics Computational Theory and Mathematics
Partner nations: United States Germany Japan

In The Last Decade

John S. Tokarski

43 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2006 The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants

Peers

Countries citing papers authored by John S. Tokarski

Since Specialization

Citations

This map shows the geographic impact of John S. Tokarski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Tokarski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Tokarski more than expected).

Fields of papers citing papers by John S. Tokarski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Tokarski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Tokarski. The network helps show where John S. Tokarski may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John S. Tokarski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John S. Tokarski Line = papers co-authored together John S. Tokarski links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling Gregory Locke,J.K. Muckelbauer,John S. Tokarski,Christopher M. Barbieri,Stefan Belić,Bradley T. Falk,Jeffrey Tredup,Ying-Kai Wang	2022	3
2	The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer Chetan Padmakar Darne,Upender Velaparthi,Mark G. Saulnier,David B. Frennesson,Peiying Liu,Audris Huang,John S. Tokarski,Aberra Fura,Thomas Spires,John A. Newitt,Vanessa Spires,Mary T. Obermeier,Paul A. Elzinga,Marco M. Gottardis,Lata Jayaraman,Gregory D. Vite,Aaron Balog	2022	7
3	An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads Charu Chaudhry,Andrew J. Tebben,John S. Tokarski,R. M. Borzilleri,William J. Pitts,Jonathan Lippy,Litao Zhang	2021	4
4	Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain John S. Tokarski,Adriana Zupa-Fernandez,Jeffrey Tredup,Kristen Pike,ChiehYing Y. Chang,Dianlin Xie,Lihong Cheng,Donna L. Pedicord,J.K. Muckelbauer,Stephen R. Johnson,Sophie Wu,Suzanne C. Edavettal,Hong Yang,Mark R. Witmer,Lisa Elkin,Yuval Blat,William J. Pitts,David S. Weinstein,James R. Burke	2015	84
5	The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode Stephen T. Wrobleski,Shuqun Lin,T. G. Murali Dhar,Alaric J. Dyckman,Tianle Li,Sidney Pitt,Rosemary Zhang,Yi Fan,Arthur M. Doweyko,John S. Tokarski,Kevin Kish,Susan E. Kiefer,John S. Sack,John A. Newitt,Mark R. Witmer,Murray McKinnon,Joel C. Barrish,John H. Dodd,Gary L. Schieven,Katerina Leftheris	2013	15
6	Design, synthesis and structure–activity relationships of novel biarylamine-based Met kinase inhibitors David Williams,Xiaotao Chen,Christine M. Tarby,Robert F. Kaltenbach,Zhen‐Wei Cai,John S. Tokarski,Yongmi An,John S. Sack,Barri Wautlet,Johnni Gullo-Brown,Benjamin J. Henley,Robert Jeyaseelan,Kristen A. Kellar,Veeraswamy Manne,George L. Trainor,Louis J. Lombardo,Joseph Fargnoli,R. M. Borzilleri	2010	16
7	Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases Brian E. Fink,Derek Norris,Harold Mastalerz,Ping Chen,Bindu Goyal,Yufen Zhao,Soong‐Hoon Kim,Gregory D. Vite,Francis Y. Lee,Hongjian Zhang,Simone Oppenheimer,John S. Tokarski,Tai W. Wong,Ashvinikumar V. Gavai	2010	23
8	Multiple and Single Binding Modes of Fragment-Like Kinase Inhibitors Revealed by Molecular Modeling, Residue Type-Selective Protonation, and Nuclear Overhauser Effects Keith L. Constantine,Luciano Mueller,William J. Metzler,Patricia A. McDonnell,Gordon Todderud,Valentina Goldfarb,Yi Fan,John A. Newitt,Susan E. Kiefer,Mian Gao,David R. Tortolani,Wayne Vaccaro,John S. Tokarski	2008	11
9	Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors Zhen‐Wei Cai,Donna Wei,R. M. Borzilleri,Ligang Qian,Amrita V. Kamath,Steven Mortillo,Barri Wautlet,Benjamin J. Henley,Robert Jeyaseelan,John S. Tokarski,John T. Hunt,Rajeev S. Bhide,Joseph Fargnoli,Louis J. Lombardo	2008	21
10	Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Harold Mastalerz,Ming Chang,Ashvinikumar V. Gavai,Walter L. Johnson,David R. Langley,Francis Y. Lee,Punit Marathe,Arvind Mathur,Simone Oppenheimer,James Tarrant,John S. Tokarski,Gregory D. Vite,Dolatrai M. Vyas,Henry Ν. C. Wong,Tai W. Wong,Hongjian Zhang,Guifen Zhang	2007	24
11	Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA Soong‐Hoon Kim,John S. Tokarski,Kenneth J. Leavitt,Brian E. Fink,Mark Salvati,Robert V. Moquin,Mary T. Obermeier,George L. Trainor,Gregory G. Vite,Linda K. Stadnick,Jonathan Lippy,Dan You,Matthew V. Lorenzi,Ping Chen	2007	19
12	Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3 Brian E. Fink,Ashvinikumar V. Gavai,John S. Tokarski,Bindu Goyal,Raj N. Misra,Hai‐Yun Xiao,S. David Kimball,Wen-Ching Han,Derek Norris,Thomas Spires,Dan You,Marco M. Gottardis,Matthew V. Lorenzi,Gregory D. Vite	2006	36
13	New dual inhibitors of EGFR and HER2 protein tyrosine kinases Brian E. Fink,Gregory D. Vite,Harold Mastalerz,John F. Kadow,Soong‐Hoon Kim,Kenneth J. Leavitt,Karen Du,Donald Crews,Toomas Mitt,Tai W. Wong,John T. Hunt,Dolatrai M. Vyas,John S. Tokarski	2005	37
14	Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors R. M. Borzilleri,Zhen‐Wei Cai,Christopher D. Ellis,Joseph Fargnoli,Aberra Fura,Tracy Gerhardt,Bindu Goyal,John T. Hunt,Steven Mortillo,Ligang Qian,John S. Tokarski,Viral Vyas,Barri Wautlet,Xioping Zheng,Rajeev S. Bhide	2005	24
15	Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases Raj N. Misra,Hai‐Yun Xiao,David Williams,Kyoung S. Kim,Songfeng Lu,Kristen Keller,Janet G. Mulheron,Roberta S. Batorsky,John S. Tokarski,John S. Sack,S. David Kimball,Francis Y. Lee,Kevin R. Webster	2004	47
16	The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists Aaron Balog,Mark Salvati,Weifang Shan,Arvind Mathur,Leslie Leith,Donna Wei,Ricardo M. Attar,Jieping Geng,Cheryl A. Rizzo,Chihuei Wang,Stanley R. Krystek,John S. Tokarski,John T. Hunt,Marco M. Gottardis,Roberto Weinmann	2004	25
17	The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor. John S. Tokarski,John A. Newitt,Francis Y. Lee,Louis J. Lombardo,R. M. Borzilleri,Kevin Kish,Dianlin Xie,Yaqun Zhang,Janet Cheng,Susan E. Kiefer,Chieh Ying J. Chang,Herbert E. Klei	2004	21
18	1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases Raj N. Misra,David B. Rawlins,Hai-yun Xiao,Weifang Shan,Isia Bursuker,Kristin A. Kellar,Janet G. Mulheron,John S. Sack,John S. Tokarski,S. David Kimball,Kevin R. Webster	2003	55
19	Molecular Modeling of Polymers 16. Gaseous Diffusion in Polymers: A Quantitative Structure-Property Relationship (QSPR) Analysis Hitesh Patel,John S. Tokarski,A. J. Hopfinger	1997	20
20	Molecular Shape and QSAR Analyses of a Family of Substituted Dichlorodiphenyl Aromatase Inhibitors Péter Nagy,John S. Tokarski,A. J. Hopfinger	1994	6

About John S. Tokarski

John S. Tokarski is a scholar working on Oncology, Cell Biology and Genetics, having authored 43 papers that have together received 2.0k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (7 papers), Microtubule and mitosis dynamics (6 papers), HER2/EGFR in Cancer Research (6 papers), Cancer-related Molecular Pathways (5 papers), Cytokine Signaling Pathways and Interactions (5 papers), Melanoma and MAPK Pathways (4 papers), Cancer therapeutics and mechanisms (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). The work is most often cited by research in Hematology (419 citations), Genetics (334 citations) and Computational Theory and Mathematics (450 citations). John S. Tokarski has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include A. J. Hopfinger, Louis J. Lombardo, Dianlin Xie, Shen Wang, Chaya Duraiswami, Magaly Girão Albuquerque, Susan E. Kiefer, John A. Newitt, Kevin Kish and Yaqun Zhang.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact